{
    "2021-09-18": [
        [
            {
                "time": "",
                "original_text": "重慶智飛生物換屆 蔣仁生繼續任董事長 擬使用不超過30億元自有資金進行現金管理",
                "features": {
                    "keywords": [
                        "重慶智飛生物",
                        "蔣仁生",
                        "董事長",
                        "30億元",
                        "自有資金",
                        "現金管理"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "醫療",
                        "生物技術"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "醫藥行業「專精特新」專題報告：走進「新」時代",
                "features": {
                    "keywords": [
                        "醫藥行業",
                        "專精特新",
                        "專題報告",
                        "新時代"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "醫療",
                        "製藥"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "雙抗藥物爆發，40多家藥企布局",
                "features": {
                    "keywords": [
                        "雙抗藥物",
                        "爆發",
                        "藥企",
                        "布局"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "醫療",
                        "製藥"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}